Login
AngioDynamics NASDAQ: ANGO
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease
| Name | AngioDynamics |
| Ticker | ANGO |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Specialized Medical Devices |
| Price | 9.34 |
| 52W Low/High | 8.26 / 19.26 |
| Market cap | 352 M |
| 1Y Total Return |
-49.62%
Weak |
| 1Y Volatility |
61.88%
More Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease
Details
| Ticker | ANGO |
| Name | AngioDynamics |
| ISIN | US03475V1017 |
| CUSIP | 03475V101 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Specialized Medical Devices |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | US S&P Small Cap 600 |
Share as of 9/17/20
| Close Price | 9.34 |
| 52W Low/High | 8.26 / 19.26 |
| Market cap | 352 M |
| 1Y Total Return |
-49.62%
Weak |
| 1Y Volatility |
61.88%
More Risk |
| Beta | 0.48 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -63.1% |
| Cash from Op. / Cur. Liabilities | -0.28 |
| Diluted Earnings / Share | -4.39 |
| ROE | - |
| ROIC | -33.4% |
| Price / Revenue | 1.3 |
| Price / Book | 0.8 |
| Price / CF | -24.4 |
| Current Ratio | 3.0 |
| Cur.Liabilities / Tot.Liabilities | 0.4 |
| Financial Leverage | 0.09 |
| in Mils USD |
rolling-year up to June
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
264
|
271
|
262
|
270
|
354
|
357
|
|
| Gross Profit |
150
|
156
|
144
|
144
|
174
|
177
|
|
| R&D |
30
|
28
|
24
|
24
|
25
|
27
|
|
| EBITDA |
-141
|
89
|
32
|
25
|
28
|
26
|
|
| Operating Income |
-179
|
-16
|
-14
|
-26
|
2
|
-9
|
|
| Net Income exc. Extra |
-
|
61
|
16
|
5
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
38
|
37
|
37
|
37
|
36
|
36
|
|
| EPS exc. Extra |
-4.39
|
1.64
|
0.44
|
0.14
|
-1.21
|
-0.09
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
594
|
836
|
705
|
708
|
726
|
774
|
|
| Cash, Eq & Invt ShortTerm |
54
|
228
|
75
|
49
|
34
|
20
|
|
| Total Current Assets |
153
|
315
|
168
|
154
|
146
|
156
|
|
| Total Non-Current Assets |
441
|
521
|
537
|
554
|
580
|
618
|
|
| Intangibles |
398
|
493
|
398
|
507
|
528
|
543
|
|
| Total Liabilities |
139
|
222
|
163
|
193
|
219
|
229
|
|
| Total Current Liabilities |
51
|
73
|
57
|
72
|
67
|
61
|
|
| Long Term Debt |
88
|
148
|
106
|
121
|
152
|
167
|
|
| Shareholder equity |
455
|
615
|
543
|
515
|
507
|
545
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-15
|
37
|
41
|
56
|
45
|
26
|
|
| Depreciation |
26
|
26
|
23
|
25
|
28
|
30
|
|
| Cash from Investing |
-63
|
83
|
-4
|
-3
|
-8
|
-13
|
|
| Capex |
7
|
3
|
2
|
3
|
2
|
12
|
|
| Cash from Financing |
-95
|
34
|
-12
|
-38
|
-24
|
-10
|
|
| Stock Issued |
-1
|
2
|
3
|
-3
|
2
|
6
|
|
| Debt (LT) Issued |
-93
|
40
|
-5
|
-24
|
-16
|
-5
|
|
| Free Cash Flow |
-181
|
137
|
-10
|
20
|
36
|
-1
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
22.7%
|
6.2%
|
1.9%
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
2,299.9%
|
-
|
|
| Current Ratio |
3.0
|
4.3
|
2.9
|
2.2
|
2.2
|
2.5
|
|
| Financial Leverage D/E |
0.09
|
0.21
|
0.17
|
0.19
|
0.24
|
0.25
|
|
| Return on Capital Avg |
-33.4%
|
18.9%
|
-5.7%
|
-0.1%
|
0.1%
|
-1.3%
|
|
| Return on Shareholder Equity |
-
|
10.6%
|
3.1%
|
1.0%
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available